Welcome to our dedicated page for ACCUSTEM SCIENCES news (Ticker: ACUT), a resource for investors and traders seeking the latest updates and insights on ACCUSTEM SCIENCES stock.
AccuStem Sciences Inc (ACUT) is a biotechnology innovator advancing stem cell research and regenerative medicine solutions. This page provides investors and industry professionals with direct access to the company's official announcements, financial updates, and scientific developments.
Track ACUT's progress through curated press releases covering clinical trial milestones, regulatory filings, and strategic partnerships. Our repository ensures you stay informed about advancements in cellular therapies and biotechnological innovations without speculative commentary.
Discover updates across key categories including quarterly earnings reports, intellectual property developments, and collaborative research initiatives. Each entry is timestamped for reference and formatted for clarity across devices.
Bookmark this page for streamlined access to AccuStem's evolving story in medical science. Verify critical information directly from primary sources before making data-driven decisions.
AccuStem Sciences (OTCQB: ACUT) announced an expansion of blood-based testing capabilities through its partnership with EmeritusDX. The collaboration includes the installation of the Promega Maxwell RSC system at EmeritusDX for high-throughput microRNA extraction from blood samples.
This expansion will support AccuStem's MSC test, the first diagnostic using microRNAs to stratify lung nodules for malignancy risk. Additionally, EmeritusDX has increased its sales force by 35% and launched the Syntara™ platform for personalized treatment strategies in hematologic diseases.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer outcomes, has announced that CEO Wendy Blosser will present at the Life Sciences Virtual Investor Forum on September 18th, 2025 at 2:30 PM EST.
The interactive online presentation will showcase AccuStem's product portfolio, which focuses on innovative molecular testing and tumor "stemness" analysis for cancer screening, treatment, and monitoring. Investors can participate in real-time Q&A and schedule one-on-one meetings from September 19-24. An archived webcast will be available for those unable to attend live.
AccuStem Sciences (OTCQB: ACUT) and EmeritusDX have expanded their strategic partnership to commercialize the MSC test for lung cancer screening. The test analyzes 24 microRNAs to differentiate between high and low-risk lung nodules identified through low-dose computed tomography (LDCT).
The partnership aims to enhance lung nodule stratification accuracy, improve patient outcomes, and reduce healthcare costs. The companies plan to launch the MSC test in US clinics in 2026, targeting the 1.6 million patients diagnosed annually with lung nodules in the United States.
The collaboration will utilize EmeritusDX's CLIA-certified laboratory and commercial infrastructure alongside AccuStem's cancer screening technologies. Both companies will pursue reimbursement strategies to broaden access to the MSC test.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, announced that Board Chairman Gabriele Cerrone has purchased an additional 5,000 shares of ACUT stock in the open market. This acquisition increases Cerrone's total holdings to 4,915,759 shares of the company.
AccuStem Sciences (OTCQB: ACUT) has signed a development agreement to access blood samples from the Rete Italiana di Screening Polmonare (RISP) clinical trial for its microRNA Signature Classifier (MSC) test development. The trial spans 18 centers in Italy.
The MSC test analyzes 24 miRNAs in plasma samples from patients with lung nodules to enhance low dose computed tomography (LDCT) screening accuracy. The MILD trial showed that combining MSC with LDCT could reduce false positive rates by a factor of five. The test has been validated across 5,000+ patients in multiple prospective trials.
The agreement includes statistical and analytical support to help AccuStem establish and commercialize the MSC test in the US, with a planned launch in 2026. The technology aims to improve patient triage, enhance outcomes, and reduce healthcare costs when used in conjunction with LDCT screening.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, announced that Board Chairman Gabriele Cerrone has purchased 38,000 additional company shares in the open market. This acquisition increases Cerrone's total holdings to 4,910,759 shares.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, has announced that Board Chairman Gabriele Cerrone has increased his stake in the company. The Chairman purchased 152,802 additional ACUT shares through open market transactions, bringing his total shareholding to 4,872,759 shares.
AccuStem Sciences (OTCQB: ACUT) announces plans to launch its microRNA Signature Classifier (MSC) blood test for lung cancer screening in the US. The test will initially target 1.6 million patients diagnosed yearly with nodules, with potential expansion to 15 million at-risk patients qualifying for annual screening.
The MSC test, developed at Istituto Nazionale Tumori, has been evaluated in over 5,000 patients across multiple clinical trials. When combined with low dose computed tomography (LDCT), MSC reduced false positive rates from 19.4% to 3.7%. The BioMILD trial showed MSC+ patients are four times more likely to have or develop lung cancer compared to MSC- patients.
AccuStem aims to commercialize the test in the US in 2026, potentially reducing unnecessary lung biopsies and healthcare costs. The company sees this as a significant opportunity to improve care outcomes for patients with lung nodules and plans to expand its use as a pre-screening tool before LDCT.
FAQ
What is the current stock price of ACCUSTEM SCIENCES (ACUT)?
What is the market cap of ACCUSTEM SCIENCES (ACUT)?
